Opinion & analysis

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

As the pharmaceuticals industry gets its issues with data integrity under control, a new challenge has arisen, according to US FDA comments at a recent meeting of the International Society for Pharmaceutical Engineering. Find out how these out-of-specification investigation (OOS) issues are playing out, with expert reporting from Pink Sheet.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments

Pharma’s New R&D Models: Federating Innovation

New Year Present For Takeda As Shire Close Nears?

Farxiga Data Change Heart Failure Treatment Outlook

It’s Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

Two More EU Notified Bodies But Not On Nando Yet

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

Ranitidine Recalls Begin In Europe As Regulators Take Action

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Germany Begins The Year With Two Possible Rx-To-OTC Switches

Thinking about using CMMI? Here are tips from the experts

Special Report: The Intersection Between Tech and Pharma (Part 1. Google)

UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

Paying For Gene Therapy: Will Pharma Be First In Line?

US FDA May Largely Avoid House Democrats’ Investigation Agenda

The Advantages Of Providing Access To Unlicensed Medicines

The Blockbusters No One Talks About

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

J&J CEO Sees Victory Ahead On Talc, Growth From Johnson’s Relaunch

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

‘Implant Files’: New Device-Failure Database Benefits Companies And Savvy Consumers, But May Befuddle Others, Experts Say

Goodbye To All That: EMA Leaves London After 24 years

Infographic – 2018 Pharma Pipeline Snapshot

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

FDA Determined To Update Cosmetics Regs After Claire’s Refuses To Recall Asbestos-Tainted Makeup